FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743198652> ?p ?o ?g. }

• W2743198652 endingPage "907" @default.
• W2743198652 startingPage "895" @default.
• W2743198652 abstract "Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-C) levels, contributes substantially to the development of coronary artery disease and the risk for cardiovascular events. As the first-line pharmacotherapy, statins have been shown to reduce both LDL-C levels and cardiovascular events. However, despite intensive statin therapy, a sizable proportion of statin-treated patients are unable to achieve the recommended target LDL-C levels, and not all patients can avoid future cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis by enhancing the degradation of hepatic low-density lipoprotein receptor (LDLR). Owing to its importance in lipid metabolism, PCSK9 has emerged as a novel pharmacological target for lowering LDL-C levels. In this review, the potential role of circulating PCSK9 as a new biomarker of lipid metabolism is described. Next, previous studies evaluating the effects of lipid-modifying pharmacological agents, particularly statins, on circulating PCSK9 concentrations are summarized. Statins decrease hepatic intracellular cholesterol, resulting in increased LDLRs as well as increased PCSK9 protein. There is a clear dose-response effect of statin treatment on PCSK9 level, as increasing doses of statins also increase the level of circulating PCSK9. Finally, the available therapeutic strategies to inhibit PCSK9 are present. Monoclonal antibodies against PCSK9, in combination with statins, are one of the most promising and novel approaches to achieve further reduction of LDL-C levels and reduce the risk of cardiovascular events." @default.
• W2743198652 created "2017-08-17" @default.
• W2743198652 creator A5091606231 @default.
• W2743198652 date "2017-01-01" @default.
• W2743198652 modified "2023-10-14" @default.
• W2743198652 title "Lipid Lowering Therapy and Circulating PCSK9 Concentration" @default.
• W2743198652 cites W121888607 @default.
• W2743198652 cites W1485967434 @default.
• W2743198652 cites W161816689 @default.
• W2743198652 cites W162053157 @default.
• W2743198652 cites W1870863005 @default.
• W2743198652 cites W1963500532 @default.
• W2743198652 cites W1964641521 @default.
• W2743198652 cites W1966941449 @default.
• W2743198652 cites W1968488102 @default.
• W2743198652 cites W1976691226 @default.
• W2743198652 cites W1977734240 @default.
• W2743198652 cites W1987486422 @default.
• W2743198652 cites W1989492995 @default.
• W2743198652 cites W1998798806 @default.
• W2743198652 cites W2001314633 @default.
• W2743198652 cites W2001328643 @default.
• W2743198652 cites W2001813316 @default.
• W2743198652 cites W2004130102 @default.
• W2743198652 cites W2005508864 @default.
• W2743198652 cites W2012070467 @default.
• W2743198652 cites W2013982259 @default.
• W2743198652 cites W2022091167 @default.
• W2743198652 cites W2024930123 @default.
• W2743198652 cites W2027196973 @default.
• W2743198652 cites W2028074615 @default.
• W2743198652 cites W2029459374 @default.
• W2743198652 cites W2030469973 @default.
• W2743198652 cites W2033190007 @default.
• W2743198652 cites W2033556017 @default.
• W2743198652 cites W2034844930 @default.
• W2743198652 cites W2035621451 @default.
• W2743198652 cites W2040612932 @default.
• W2743198652 cites W2043461445 @default.
• W2743198652 cites W2045995934 @default.
• W2743198652 cites W2046181127 @default.
• W2743198652 cites W2047558053 @default.
• W2743198652 cites W2047695409 @default.
• W2743198652 cites W2047908832 @default.
• W2743198652 cites W2053490104 @default.
• W2743198652 cites W2053653961 @default.
• W2743198652 cites W2054610237 @default.
• W2743198652 cites W2056455339 @default.
• W2743198652 cites W2057479072 @default.
• W2743198652 cites W2058573028 @default.
• W2743198652 cites W2058944413 @default.
• W2743198652 cites W2063025601 @default.
• W2743198652 cites W2064994526 @default.
• W2743198652 cites W2067539811 @default.
• W2743198652 cites W2068603806 @default.
• W2743198652 cites W2071154679 @default.
• W2743198652 cites W2076648603 @default.
• W2743198652 cites W2083941082 @default.
• W2743198652 cites W2096075279 @default.
• W2743198652 cites W2099654648 @default.
• W2743198652 cites W2102467926 @default.
• W2743198652 cites W2106759269 @default.
• W2743198652 cites W2107513378 @default.
• W2743198652 cites W2108956796 @default.
• W2743198652 cites W2110083155 @default.
• W2743198652 cites W2119708151 @default.
• W2743198652 cites W2120597207 @default.
• W2743198652 cites W2121581403 @default.
• W2743198652 cites W2123936150 @default.
• W2743198652 cites W2125528229 @default.
• W2743198652 cites W2126229169 @default.
• W2743198652 cites W2127729207 @default.
• W2743198652 cites W2128030263 @default.
• W2743198652 cites W2129166365 @default.
• W2743198652 cites W2131607570 @default.
• W2743198652 cites W2133806624 @default.
• W2743198652 cites W2139575534 @default.
• W2743198652 cites W2140380288 @default.
• W2743198652 cites W2140622082 @default.
• W2743198652 cites W2142231197 @default.
• W2743198652 cites W2146010644 @default.
• W2743198652 cites W2148577580 @default.
• W2743198652 cites W2154862144 @default.
• W2743198652 cites W2155259933 @default.
• W2743198652 cites W2157115489 @default.
• W2743198652 cites W2158286233 @default.
• W2743198652 cites W2160761735 @default.
• W2743198652 cites W2166900112 @default.
• W2743198652 cites W2177788247 @default.
• W2743198652 cites W2247997571 @default.
• W2743198652 cites W2259605437 @default.
• W2743198652 cites W2287953281 @default.
• W2743198652 cites W2294569099 @default.
• W2743198652 cites W2346825268 @default.
• W2743198652 cites W2523595269 @default.
• W2743198652 cites W2554832534 @default.
• W2743198652 cites W2587186420 @default.
• W2743198652 cites W2594863542 @default.

• next